Desmopressin in the treatment of nocturia: clinical evidence and experience
- PMID:24294289
- PMCID: PMC3825109
- DOI: 10.1177/1756287213502116
Desmopressin in the treatment of nocturia: clinical evidence and experience
Abstract
Nocturia is a common and bothersome condition experienced by both men and women. Studies have suggested that nocturia contributes a level of morbidity to those who suffer from the condition, both young and old. Desmopressin has historically been utilized to treat conditions such as central diabetes insipidus, certain bleeding disorders and primary nocturnal enuresis. Recently, interest has increased as to the use of desmopressin (a vasopressin analog) in the treatment of adult nocturia, for whom nocturnal polyuria is prevalent. While desmopressin has been traditionally administered in tablet and bioequivalent high dose melt formulations, newer low-dose orally disintegrating sublingual desmopressin has been recently studied to determine safe and efficacious dosing strategies. In this review, nocturia and its associated morbidities are discussed, followed by a contemporary literature review regarding the safety and efficacy of desmopressin for its treatment.
Keywords: DDAVP; LUTS; desmopressin; nocturia; nocturnal polyuria.
Conflict of interest statement
Figures
Similar articles
- Desmopressin and nocturnal voiding dysfunction: Clinical evidence and safety profile in the treatment of nocturia.Chung E.Chung E.Expert Opin Pharmacother. 2018 Feb;19(3):291-298. doi: 10.1080/14656566.2018.1429406. Epub 2018 Jan 29.Expert Opin Pharmacother. 2018.PMID:29376448Review.
- Desmopressin for nocturia in adults.[No authors listed][No authors listed]Drug Ther Bull. 2017 Mar;55(3):30-32. doi: 10.1136/dtb.2017.3.0460.Drug Ther Bull. 2017.PMID:28279978
- Desmopressin acetate the first sublingual tablet to treat nocturia due to nocturnal polyuria.Alford N, Hashim H.Alford N, et al.Expert Rev Clin Pharmacol. 2021 Aug;14(8):939-954. doi: 10.1080/17512433.2021.1931122. Epub 2021 Jun 14.Expert Rev Clin Pharmacol. 2021.PMID:33993824Review.
- Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study.Sand PK, Dmochowski RR, Reddy J, van der Meulen EA.Sand PK, et al.J Urol. 2013 Sep;190(3):958-64. doi: 10.1016/j.juro.2013.02.037. Epub 2013 Feb 20.J Urol. 2013.PMID:23454404Clinical Trial.
- Low-dose Desmopressin Orally Disintegrating Tablet: Suggested Clinically Meaningful Benefit in Patients with Nocturia Due to Nocturnal Polyuria.Weiss JP, van der Meulen EA, Juul KV.Weiss JP, et al.Eur Urol Focus. 2020 Sep 15;6(5):1006-1012. doi: 10.1016/j.euf.2018.11.001. Epub 2018 Nov 22.Eur Urol Focus. 2020.PMID:30470646Clinical Trial.
Cited by
- Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects.Andersson KE, Longstreth J, Brucker BM, Campeau L, Cheng L, Francis L, Fein S.Andersson KE, et al.Pharm Res. 2019 Apr 29;36(6):92. doi: 10.1007/s11095-019-2628-1.Pharm Res. 2019.PMID:31037429Free PMC article.Clinical Trial.
- Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS).Drake MJ, Canham L, Cotterill N, Delgado D, Homewood J, Inglis K, Johnson L, Kisanga MC, Owen D, White P, Cottrell D.Drake MJ, et al.BMC Neurol. 2018 Aug 6;18(1):107. doi: 10.1186/s12883-018-1114-4.BMC Neurol. 2018.PMID:30081859Free PMC article.Clinical Trial.
- Nocturia: consequences, classification, and management.Fine ND, Weiss JP, Wein AJ.Fine ND, et al.F1000Res. 2017 Sep 1;6:1627. doi: 10.12688/f1000research.11979.1. eCollection 2017.F1000Res. 2017.PMID:29026531Free PMC article.Review.
- Korean guideline of desmopressin for the treatment of nocturia in men.Hwang EC, Jung HJ, Han MA, Kim MH, Yu SH, Jeong HC, Kim JS, Paick SH, Yeo JK, Jung JH; Korean Urological Association Guideline Development Committee.Hwang EC, et al.Investig Clin Urol. 2022 Sep;63(5):499-513. doi: 10.4111/icu.20220165.Investig Clin Urol. 2022.PMID:36067995Free PMC article.Review.
- Mechanistic insights into the slow peptide bond formation with D-amino acids in the ribosomal active site.Melnikov SV, Khabibullina NF, Mairhofer E, Vargas-Rodriguez O, Reynolds NM, Micura R, Söll D, Polikanov YS.Melnikov SV, et al.Nucleic Acids Res. 2019 Feb 28;47(4):2089-2100. doi: 10.1093/nar/gky1211.Nucleic Acids Res. 2019.PMID:30520988Free PMC article.
References
- Asplund R. (1999) Mortality in the elderly in relation to nocturnal micturition. BJU Int 84: 297–301 - PubMed
- Asplund R. (2005) Nocturia: consequences for sleep and daytime activities and associated risks. Eur Urol Supp 3: 24–32
- Bosch J., Weiss J. (2010) The prevalence and causes of nocturia. J Urol 184: 440–446 - PubMed
- Cornu J., Abrams P., Chapple C., Dmochowski R., Lemack G., Michel M., et al. (2012) A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management – a systematic review and meta-analysis. Eur Urol 62: 877–890 - PubMed
- Gulur D., Mevcha A., Drake M. (2011) Nocturia as a manifestation of systemic disease. BJU Int 107: 702–713 - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources